Abiopharma

News list

AZITRA, INC. (AZTR)

SEC News
Aug. 12, 2026, 20:55 UTC

(10% Negative) AZITRA, INC. (AZTR) Announces Delay in results Trials for ex vivo human skin Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text

News bot Aug. 12, 2026, 8:56 p.m.

📋 AZITRA, INC. (AZTR) - Clinical Trial Update

Filing Date: 2026-08-12

Accepted: 2026-08-12 16:55:16

Event Type: Clinical Trial Update

Event Details:

AZITRA, INC. (AZTR) Announces Clinical Trial Update AZITRA, INC. (AZTR) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: results
Diseases/Conditions: ex vivo human skin
Clinical Stage: Phase 1, clinical study
Update Type: Trial Timeline Adjustment
Primary Factors: Patient Enrollment, Regulatory Process, Regulatory Timeline
Collaboration: Tobacco Etch Virus
Updated Timeline: Q2 2026
- Reported the first preclinical data from ATR
- COSF demonstrating breakthrough repeat
- dose distribution, controlled delivery into targeted skin layers and anti
  - expected in Q4-2026

🔬 Clinical Development Pipeline (AZITRA, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
ATR-04	Other	Phase PHASE1	Epidermal Growth Factor	ClinicalTrials.gov
ATR12-351	Other	Phase PHASE1	Netherton Syndrome	ClinicalTrials.gov
AZT-04	Other	Approved	Study of Three Doses of AZT-04 for Skin Appearance	ClinicalTrials.gov
Placebo	Other	Phase PHASE1	Epidermal Growth Factor	ClinicalTrials.gov
Vehicle	Other	Phase PHASE1	EGFR Inhibitor-associated Rash	ClinicalTrials.gov
ATR04-484	Other	Phase PHASE1	EGFR Inhibitor-associated Rash	ClinicalTrials.gov

💼 Business Developments:

Partnership: Not available
Acquisition: Not available
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: AZITRA, INC.
Ticker Symbol: AZTR